152 related articles for article (PubMed ID: 35726496)
1. Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.
González-Sánchez E; Muñoz-Callejas A; Gómez-Román J; San Antonio E; Marengo A; Tsapis N; Bohne-Japiassu K; González-Tajuelo R; Pereda S; García-Pérez J; Cavagna L; González-Gay MÁ; Vicente-Rabaneda EF; Meloni F; Fattal E; Castañeda S; Urzainqui A
Br J Pharmacol; 2022 Sep; 179(18):4534-4548. PubMed ID: 35726496
[TBL] [Abstract][Full Text] [Related]
2. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
[TBL] [Abstract][Full Text] [Related]
3. Liposomes Loaded with Everolimus and Coated with Hyaluronic Acid: A Promising Approach for Lung Fibrosis.
Pandolfi L; Marengo A; Japiassu KB; Frangipane V; Tsapis N; Bincoletto V; Codullo V; Bozzini S; Morosini M; Lettieri S; Vertui V; Piloni D; Arpicco S; Fattal E; Meloni F
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299359
[TBL] [Abstract][Full Text] [Related]
4. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
[TBL] [Abstract][Full Text] [Related]
5. Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation.
Mattoo H; Bangari DS; Cummings S; Humulock Z; Habiel D; Xu EY; Pate N; Resnick R; Savova V; Qian G; Beil C; Rao E; Nestle FO; Bryce PJ; Subramaniam A
Am J Respir Cell Mol Biol; 2023 Oct; 69(4):404-421. PubMed ID: 37369139
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
7. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model.
Yoshizaki A; Yanaba K; Iwata Y; Komura K; Ogawa A; Akiyama Y; Muroi E; Hara T; Ogawa F; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Tedder TF; Sato S
J Immunol; 2010 Aug; 185(4):2502-15. PubMed ID: 20624949
[TBL] [Abstract][Full Text] [Related]
8. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis.
Codullo V; Cova E; Pandolfi L; Breda S; Morosini M; Frangipane V; Malatesta M; Calderan L; Cagnone M; Pacini C; Cavagna L; Recalde H; Distler JHW; Giustra M; Prosperi D; Colombo M; Meloni F; Montecucco C
J Control Release; 2019 Sep; 310():198-208. PubMed ID: 31430501
[TBL] [Abstract][Full Text] [Related]
10. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
[TBL] [Abstract][Full Text] [Related]
11. Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis.
Bogatkevich GS; Atanelishvili I; Bogatkevich AM; Silver RM
Arthritis Rheumatol; 2023 Mar; 75(3):438-448. PubMed ID: 36103378
[TBL] [Abstract][Full Text] [Related]
12. Development of an autoimmune syndrome affecting the skin and internal organs in P-selectin glycoprotein ligand 1 leukocyte receptor-deficient mice.
Pérez-Frías A; González-Tajuelo R; Núñez-Andrade N; Tejedor R; García-Blanco MJ; Vicente-Rabaneda E; Castañeda S; Gamallo C; Silván J; Esteban-Villafruela A; Cubero-Rueda L; García-García C; Muñoz-Calleja C; García-Diez A; Urzainqui A
Arthritis Rheumatol; 2014 Nov; 66(11):3178-89. PubMed ID: 25132671
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib.
Wang D; Wei Y; Xu L; Zhang J
Adv Rheumatol; 2023 May; 63(1):22. PubMed ID: 37194022
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of Psgl-1 accelerates bleomycin (BLM)-induced lung fibrosis and inflammation in mice through activating PI3K/AKT.
Han X; Wang SM
Biochem Biophys Res Commun; 2017 Sep; 491(2):558-565. PubMed ID: 28263743
[TBL] [Abstract][Full Text] [Related]
15. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis.
Meloni F; Caporali R; Marone Bianco A; Paschetto E; Morosini M; Fietta AM; Patrizio V; Bobbio-Pallavicini F; Pozzi E; Montecucco C
Sarcoidosis Vasc Diffuse Lung Dis; 2004 Jun; 21(2):111-8. PubMed ID: 15281432
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM
Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398
[TBL] [Abstract][Full Text] [Related]
17. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature.
Kowal-Bielecka O; Kowal K; Highland KB; Silver RM
Semin Arthritis Rheum; 2010 Aug; 40(1):73-88. PubMed ID: 19152959
[TBL] [Abstract][Full Text] [Related]
18. Histopathology and bronchoalveolar lavage.
Silver RM; Wells AU
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5(Suppl 5):v62-4. PubMed ID: 18784150
[TBL] [Abstract][Full Text] [Related]
19. Superiority of systemic bleomycin to intradermal HOCl for the study of interstitial lung disease.
Morozan A; Joy S; Fujii U; Fraser R; Watters K; Martin JG; Colmegna I
Sci Rep; 2023 Nov; 13(1):20577. PubMed ID: 37996447
[TBL] [Abstract][Full Text] [Related]
20. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
